Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

letter

. 2024 Sep 28;23:210. doi: 10.1186/s12943-024-02123-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

PMC Copyright notice

Fig. 2 — A high percentage of CD16+ monocytes negatively predicts patient outcome. A) Percentage of CD16+ monocytes (CD14 + + CD16+ (intermediate monocytes) or CD14 + CD16++ (nonclassical monocytes)) in aggressive B-NHL patients (patient, n = 46) at diagnosis compared to healthy controls (HC, n = 25). B) Kaplan-Meier survival curve over 24 months. Progression-free survival (PFS) for high (> 10%) and low (< 10%) percentages of CD16+ monocytes at diagnosis. C) Percentage of CD16+ monocytes at diagnosis according to patient’s IPI. (IPI 0–2, n = 25; IPI 3–5, n = 21). D) Cox proportional hazard analysis of high (> 10%) and low (< 10%) percentages of CD16+ monocytes at diagnosis in relation to IPI over 24 months. E) Representative staining of monocyte phagocytosis isolated from PBMC of a healthy donor. Monocytes were stained with anti-CD14 antibody and the target cell line WSU-DLCL2 with anti-CD19 antibody, co-cultured for 6 h without rituximab (-RTX) or with rituximab (+ RTX) and analyzed by flow cytometry. F) Percentage of monocytes that phagocytosed WSU-DLCL2 cells after co-culture of monocytes with WSU-DLCL2 cells for 6 h with (+ RTX) or without rituximab (-RTX); n = 10. G) Percentage of PD-L1+ monocytes after phagocytosis of WSU-DLCL2 cells (ADCP+) and monocytes without phagocytosing WSU-DLCL2 cells (ADCP-); n = 10. H) Kaplan-Meier survival curve over 24 months. PFS for patients with an IPI 0–2 or an IPI 3–5. I) Cox proportional hazard analysis of high (> 10%) and low (< 10%) percentages of CD16+ monocytes at diagnosis adjusted for high (> 1.6%) and low (< 1.6%) percentages of CD16+ T cells at diagnosis. CD16+ monocytes < 10%, CD16+ T cells < 1.6% (n = 13); CD16+ monocytes < 10%, CD16+ T cells > 1.6% (n = 10); CD16+ monocytes > 10%, CD16+ T cells < 1.6% (n = 18); CD16+ monocytes > 10%, CD16+ T cells > 1.6% (n = 5). J) Kaplan-Meier survival curve over 24 months. PFS for patients with a high percentage of CD16+ monocytes (> 10%) in combination with a low percentage of CD16+ T cells (< 1.6%) at diagnosis (light blue, yes) compared to patients without this combination (purple, no). In Kaplan-Meier survival curves, black marks represent censored patients. ns non-significant; ** p < 0.01; *** p < 0.001; **** p < 0.0001